The Valley Desk

NCT00129766 · Interventional trial

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Overall registry status Completed

Phase 3

Conditions Respiratory Syncytial Virus Infections

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov